Oppenheimer Asset Management Inc. reduced its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 24.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,435 shares of the medical research company’s stock after selling 7,415 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Agilent Technologies were worth $1,390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in A. Parallel Advisors LLC increased its position in Agilent Technologies by 5.3% during the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock valued at $157,000 after buying an additional 131 shares in the last quarter. Trust Co. of Vermont increased its position in Agilent Technologies by 1.8% during the 2nd quarter. Trust Co. of Vermont now owns 2,793 shares of the medical research company’s stock valued at $166,000 after buying an additional 50 shares in the last quarter. Penserra Capital Management LLC increased its position in Agilent Technologies by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 3,496 shares of the medical research company’s stock valued at $184,000 after buying an additional 304 shares in the last quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC increased its position in Agilent Technologies by 17.2% during the 2nd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 3,319 shares of the medical research company’s stock valued at $196,000 after buying an additional 486 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Agilent Technologies during the 2nd quarter valued at about $200,000.

In related news, Director Heidi Fields sold 8,625 shares of the business’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $59.53, for a total value of $513,446.25. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $61.26, for a total value of $306,300.00. Following the completion of the transaction, the insider now owns 45,138 shares in the company, valued at approximately $2,765,153.88. The disclosure for this sale can be found here. Insiders sold a total of 141,098 shares of company stock worth $8,798,933 in the last 90 days.

Shares of Agilent Technologies, Inc. (NYSE:A) opened at 65.02 on Friday. The company’s 50-day moving average price is $61.64 and its 200 day moving average price is $57.50. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $65.68. The firm has a market capitalization of $20.94 billion, a price-to-earnings ratio of 33.53 and a beta of 1.30.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.49 EPS. On average, equities research analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current fiscal year.

Several research analysts recently issued reports on the company. Wells Fargo & Company raised Agilent Technologies from a “market perform” rating to an “outperform” rating and upped their target price for the company from $42.92 to $60.73 in a research report on Wednesday, July 12th. BidaskClub raised Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. Deutsche Bank AG set a $68.00 target price on Agilent Technologies and gave the company a “buy” rating in a research report on Wednesday, August 16th. Robert W. Baird upped their target price on Agilent Technologies from $57.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, May 24th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $70.00 price objective on shares of Agilent Technologies in a report on Wednesday, August 16th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $63.91.

WARNING: “Agilent Technologies, Inc. (A) Position Cut by Oppenheimer Asset Management Inc.” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/09/agilent-technologies-inc-a-position-cut-by-oppenheimer-asset-management-inc.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Stock Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related stocks with our FREE daily email newsletter.